{"summary":"With over fifteen years\u2019 research experience, background in cancer biology and immunology, proficiency in both biochemical and cell-based assay development, I am now dedicated to contributing to drug discovery and development efforts. I am particularly engaged in large molecule therapeutics, and finding new modalities to fight cancer.","lastName":"Kovacs","objectUrn":"urn:li:member:99086681","geoRegion":"Greater Cambridge Area","fullName":"Erika Kovacs","firstName":"Erika","currentPositions":[{"companyName":"Abzena","description":"Heading up Abzena's Bioassay team, I lead an excellent team of scientists to design and develop cell-based assays most suited to our clients' needs.","title":"Senior Director, Bioassays","companyUrnResolutionResult":{"website":"http:\/\/www.abzena.com","formattedRevenue":{"unit":"MILLION","amount":5.7,"currencyCode":"GBP"},"industry":"Pharmaceutical Manufacturing","employeeCountRange":"501-1000","headquarters":{"geographicArea":"California","country":"United States","city":"San Diego","postalCode":"92121","line1":"6325 Lusk Blvd"},"revenue":{"amount":"5667000.0","currencyCode":"GBP"},"flagshipCompanyUrl":"https:\/\/www.linkedin.com\/company\/abzena\/"},"companyUrn":"urn:li:fs_salesCompany:5216276","tenureAtCompany":{"numYears":8,"numMonths":9},"startedOn":{"month":4,"year":2022}}],"entityUrn":"urn:li:fs_salesProfile:(ACwAAAXn8VkBfFJ2_na7LExOPnrJaJkiRh4pB3g,NAME_SEARCH,pvcX)","profilePictureDisplayImage":{"artifacts":[{"width":100,"fileIdentifyingUrlPathSegment":"100_100\/0\/1530785334619?e=1723075200&v=beta&t=EIODOi4vCR6rIEIZp2fhCdUp9_cm8GBX0_e4JJTfiA8","height":100},{"width":200,"fileIdentifyingUrlPathSegment":"200_200\/0\/1530785334686?e=1723075200&v=beta&t=TIpu-oiW7x8Yd9cX_9O7exu0kAII_p5KTAX3anpLW8A","height":200},{"width":400,"fileIdentifyingUrlPathSegment":"400_400\/0\/1530785334735?e=1723075200&v=beta&t=l37kGVLEFRNkWdwZLY2xU4N-h5fDuX2PL8CIyHXrCYI","height":400},{"width":500,"fileIdentifyingUrlPathSegment":"800_800\/0\/1530785334544?e=1723075200&v=beta&t=-wRRf8bSmg9lBx_5Zca5cfP623fzLHx45y0in9AGYkI","height":500}],"rootUrl":"https:\/\/media.licdn.com\/dms\/image\/C5603AQGoZnTkzcb-jw\/profile-displayphoto-shrink_"},"projects":[],"contactInfo":{},"industry":"Pharmaceutical Manufacturing","educations":[{"endedOn":{"year":2010},"degree":"Doctor of Philosophy (PhD)","eduId":167494860,"fieldsOfStudy":["Biochemistry and Molecular Biology"],"schoolName":"Eotvos Lorand University, Budapest, Hungary","startedOn":{"year":2005}},{"endedOn":{"year":2005},"degree":"Master of Science (MSc)","eduId":167495050,"fieldsOfStudy":["Biochemistry and Molecular Biology"],"schoolName":"Eotvos Lorand University, Budapest, Hungary","startedOn":{"year":2000}}],"skills":[{"numOfEndorsement":22,"name":"Biochemistry"},{"numOfEndorsement":15,"name":"Molecular Biology"},{"numOfEndorsement":12,"name":"Flow Cytometry"},{"numOfEndorsement":10,"name":"Fluorescence Microscopy"},{"numOfEndorsement":10,"name":"Cell Biology"},{"numOfEndorsement":2,"name":"Fluorescence Spectroscopy"},{"numOfEndorsement":1,"name":"Cell Signaling"},{"numOfEndorsement":3,"name":"Assay Development"},{"numOfEndorsement":0,"name":"Binding Assays"},{"numOfEndorsement":2,"name":"Enzyme Assays"},{"numOfEndorsement":1,"name":"Cell Based Assays"},{"numOfEndorsement":3,"name":"Antibodies"},{"numOfEndorsement":0,"name":"Immunofluorescence"},{"numOfEndorsement":1,"name":"ELISA"},{"numOfEndorsement":1,"name":"Western Blotting"},{"numOfEndorsement":2,"name":"Protein Engineering"},{"numOfEndorsement":2,"name":"Molecular Cloning"},{"numOfEndorsement":0,"name":"Site-directed Mutagenesis"},{"numOfEndorsement":0,"name":"Surface Plasmon Resonance"},{"numOfEndorsement":3,"name":"Transfection"},{"numOfEndorsement":3,"name":"PCR"},{"numOfEndorsement":2,"name":"Protein Purification"}],"numOfConnections":454,"patents":[],"headline":"Senior Director, Bioassays at Abzena","courses":[],"certifications":[],"memberBadges":{"premium":false,"openLink":false,"jobSeeker":false},"flagshipProfileUrl":"https:\/\/www.linkedin.com\/in\/erika-kovacs-9b522529","organizations":[],"location":"Greater Cambridge Area","publications":[{"name":"Analysis of the Role of the C-Terminal Tail in the Regulation of the Epidermal Growth Factor Receptor","publishedOn":{"month":9,"day":1,"year":2015},"publisher":"Molecular and Cellular Biology","url":"http:\/\/mcb.asm.org\/content\/35\/17\/3083.long","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAXn8VkBfFJ2_na7LExOPnrJaJkiRh4pB3g,NAME_SEARCH,pvcX)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAKdt_QBO3dFJcYEuVYl-2nP--JCK90P8wI,NAME_SEARCH,quAq)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAARP4UkB5IW1Can_cpE1RyZVFweGkBfO9fY,NAME_SEARCH,ykTu)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAWyAc0BBdjISSBlN6f36vzPT_3NqKyzuNs,NAME_SEARCH,_Opw)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAcdKfIB_GPnf4huNhw8TMjL6I6Ahst23Vg,NAME_SEARCH,u63n)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAKJjoIBqXk-EZ-oWUxLKnQXH4DzsMANi0s,NAME_SEARCH,QOuW)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAD7clMBoNGbBBCxxCpDLVtWLG-XcKcNZMI,NAME_SEARCH,mEPf)"}]},{"name":"A Structural Perspective on the Regulation of the Epidermal Growth Factor Receptor","publishedOn":{"month":1,"day":1,"year":2015},"publisher":"Annual Reviews in Biochemistry","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAXn8VkBfFJ2_na7LExOPnrJaJkiRh4pB3g,NAME_SEARCH,pvcX)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAcdKfIB_GPnf4huNhw8TMjL6I6Ahst23Vg,NAME_SEARCH,u63n)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAKJjoIBqXk-EZ-oWUxLKnQXH4DzsMANi0s,NAME_SEARCH,QOuW)"}]},{"name":"Conformational coupling across the plasma membrane in activation of the EGF receptor","publishedOn":{"month":1,"day":31,"year":2013},"publisher":"Cell","url":"http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0092867412015541","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAXn8VkBfFJ2_na7LExOPnrJaJkiRh4pB3g,NAME_SEARCH,pvcX)"}]},{"name":"Regulation of the catalytic activity of the EGF receptor","publishedOn":{"month":12,"day":31,"year":2011},"publisher":"Current Opinion in Structural Biology","url":"http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0959440X11001308","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAXn8VkBfFJ2_na7LExOPnrJaJkiRh4pB3g,NAME_SEARCH,pvcX)"}]},{"name":"Regulation of ryanodine receptors by sphingosylphosphorylcholine: Involvement of both calmodulin-dependent and-independent mechanisms","publishedOn":{"month":10,"day":15,"year":2010},"publisher":"Biochemical and Biophysical Research Communications","url":"http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0006291X10017341","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAXn8VkBfFJ2_na7LExOPnrJaJkiRh4pB3g,NAME_SEARCH,pvcX)"}]},{"name":"Structure and mechanism of calmodulin binding to a signaling sphingolipid reveal new aspects of lipid-protein interactions","publishedOn":{"month":10,"day":1,"year":2010},"publisher":"The FASEB Journal","url":"http:\/\/www.fasebj.org\/content\/24\/10\/3829.short","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAXn8VkBfFJ2_na7LExOPnrJaJkiRh4pB3g,NAME_SEARCH,pvcX)"}]},{"name":"Dual coding in alternative reading frames correlates with intrinsic protein disorder","publishedOn":{"month":3,"day":23,"year":2010},"publisher":"Proceedings of the National Academy of Sciences","url":"http:\/\/www.pnas.org\/content\/107\/12\/5429.short","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAXn8VkBfFJ2_na7LExOPnrJaJkiRh4pB3g,NAME_SEARCH,pvcX)"}]},{"name":"Dissociation of Calmodulin-Target Peptide Complexes by the Lipid Mediator Sphingosylphosphorylcholine: Implications in Calcium Signaling","publishedOn":{"month":1,"day":15,"year":2010},"publisher":"Journal of Biological Chemistry","url":"http:\/\/www.jbc.org\/content\/285\/3\/1799.short","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAXn8VkBfFJ2_na7LExOPnrJaJkiRh4pB3g,NAME_SEARCH,pvcX)"}]},{"name":"Mechanism of lysophosphatidic acid-induced amyloid fibril formation of \u03b22-microglobulin in vitro under physiological conditions","publishedOn":{"month":5,"day":27,"year":2009},"publisher":"Biochemistry","url":"http:\/\/pubs.acs.org\/doi\/abs\/10.1021\/bi900356r","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAXn8VkBfFJ2_na7LExOPnrJaJkiRh4pB3g,NAME_SEARCH,pvcX)"}]},{"name":"Sphingosylphosphorylcholine as a novel calmodulin inhibitor","publishedOn":{"month":3,"day":1,"year":2008},"publisher":"Biochem. J","url":"http:\/\/www.biochemj.org\/bj\/410\/bj4100427.htm","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAXn8VkBfFJ2_na7LExOPnrJaJkiRh4pB3g,NAME_SEARCH,pvcX)"}]}],"positions":null,"posts":[{"createdAt":1714124580000,"insightId":"215f0d2e-188a-4bbb-9784-c443309f3233","activityUnion":{"postActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":19}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:activity:7189559687833378816","threadUrn":"urn:li:activity:7189559687833378816","reactionsCount":19,"commentsCount":0,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7189559687397154817","message":{"attributes":[],"text":"So proud to be launching this fantastic new immunogenicity assessment tool! Please get in touch if you want to hear more about how it can support your program."},"rootActivity":{"contentSummaryUnion":{"mediaContentSummary":{"mediaType":"STILLIMAGE","thumnailUrl":"https:\/\/media.licdn.com\/dms\/image\/D5622AQHQYxjpuXDjqw\/feedshare-shrink_2048_1536\/0\/1714067833694?e=1720051200&v=beta&t=cfjj-aDJrbjXQGH9u_3oJvYa0rxXaRIk0XEICo2-HrE"}},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7189321573487513600","message":{"attributes":[{"start":48,"length":9,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:bioassay"}}},{"start":172,"length":15,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:immunogenicity"}}},{"start":462,"length":22,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:9854840"}}},{"start":722,"length":5,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:adcs"}}},{"start":1050,"length":24,"value":{"com.linkedin.common.HyperlinkAttributedEntity":{"url":"https:\/\/lnkd.in\/gVg_Gmcy"}}},{"start":1076,"length":5,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:cdmo"}}},{"start":1082,"length":4,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:cro"}}},{"start":1087,"length":16,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:drugdevelopment"}}},{"start":1104,"length":10,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:biologics"}}},{"start":1115,"length":14,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:bioconjugates"}}}],"text":"Abzena has announced the launch of its enhanced #bioassay platform EpiScreen\u00ae 2.0, a comprehensive suite of assays that predict and evaluate potential risks of preclinical #immunogenicity in protein, antibody, and gene therapy therapeutics. \n\nThe next generation tool provides a better immunogenic assessment that is highly sensitive, multi-parametric, and data-rich, which ultimately improves candidate selection and de-risks early phase development.\n\nOur CSO, Campbell Bunce PhD MBA shares, \u201cWe developed EpiScreen\u00ae 2.0 because we understand that there are many factors that contribute to the immunogenicity risk of a drug, especially with the next-generation therapeutics being developed like antibody-drug conjugates (#ADCs).\u00a0 I\u2019m not aware of any other service provider that offers such an extensive set of immunogenicity assessment capabilities covering bioinformatics, proteomics, and ex vivo human immune cell assays underpinned by a high-throughput, high-quality infrastructure for blood processing and storage.\" \n\nAccess the press release: https:\/\/lnkd.in\/gVg_Gmcy\n\n#CDMO #CRO #drugdevelopment #biologics #bioconjugates"},"entityUrn":"urn:li:share:7189321573487513600"},"entityUrn":"urn:li:share:7189559687397154817"}}}]}